Skyline Venture Management Iv, Llc - Net Worth and Insider Trading

Skyline Venture Management Iv, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Skyline Venture Management Iv, Llc owns 4 companies in total, including Protara Therapeutics Inc (TARA) , Tetraphase Pharmaceuticals Inc (TTPH) , and Talphera Inc (TLPH) among others .

Click here to see the complete history of Skyline Venture Management Iv, Llc’s form 4 insider trades.

Insider Ownership Summary of Skyline Venture Management Iv, Llc

Ticker	Comapny	Transaction Date	Type of Owner
TARA	Protara Therapeutics Inc	2014-10-21	10 percent owner
TTPH	Tetraphase Pharmaceuticals Inc	2014-03-12	10 percent owner
TLPH	Talphera Inc	2012-05-29	10 percent owner
		2014-02-12	10 percent owner

Skyline Venture Management Iv, Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Skyline Venture Management Iv, Llc Ownership Network

Ownership Network List of Skyline Venture Management Iv, Llc

No Data

Ownership Network Relation of Skyline Venture Management Iv, Llc

Skyline Venture Management Iv, Llc Owned Company Details

What does Protara Therapeutics Inc do?

Who are the key executives at Protara Therapeutics Inc?

Skyline Venture Management Iv, Llc is the 10 percent owner of Protara Therapeutics Inc. Other key executives at Protara Therapeutics Inc include 10 percent owner Opaleye Management Inc. , Chief Financial Officer Patrick Fabbio , and director & CEO and President Jesse Shefferman .

Protara Therapeutics Inc (TARA) Insider Trades Summary

Over the past 18 months, Skyline Venture Management Iv, Llc made no insider transaction in Protara Therapeutics Inc (TARA). Other recent insider transactions involving Protara Therapeutics Inc (TARA) include a net sale of 703,460 shares made by Opaleye Management Inc. ,

In summary, during the past 3 months, insiders sold 220,893 shares of Protara Therapeutics Inc (TARA) in total and bought 0 shares, with a net sale of 220,893 shares. During the past 18 months, 703,460 shares of Protara Therapeutics Inc (TARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 703,460 shares.

Protara Therapeutics Inc (TARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protara Therapeutics Inc Insider Transactions

No Available Data

What does Tetraphase Pharmaceuticals Inc do?

Who are the key executives at Tetraphase Pharmaceuticals Inc?

Skyline Venture Management Iv, Llc is the 10 percent owner of Tetraphase Pharmaceuticals Inc. Other key executives at Tetraphase Pharmaceuticals Inc include director & See Remarks Larry G. Edwards , director & 10 percent owner Steven Boyd , and director & 10 percent owner Armistice Capital Master Fund Ltd. .

Tetraphase Pharmaceuticals Inc (TTPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tetraphase Pharmaceuticals Inc (TTPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tetraphase Pharmaceuticals Inc (TTPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tetraphase Pharmaceuticals Inc (TTPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tetraphase Pharmaceuticals Inc Insider Transactions

No Available Data

What does Talphera Inc do?

Who are the key executives at Talphera Inc?

Skyline Venture Management Iv, Llc is the 10 percent owner of Talphera Inc. Other key executives at Talphera Inc include director & Chief Executive Officer Vincent J. Angotti , director & Chief Medical Officer Pamela P Palmer , and Chief Engineering Officer Badri N Dasu .

Talphera Inc (TLPH) Insider Trades Summary

Over the past 18 months, Skyline Venture Management Iv, Llc made no insider transaction in Talphera Inc (TLPH). Other recent insider transactions involving Talphera Inc (TLPH) include a net purchase of 37,260 shares made by Vincent J. Angotti , and a net sale of 16,956 shares made by Pamela P Palmer .

In summary, during the past 3 months, insiders sold 0 shares of Talphera Inc (TLPH) in total and bought 7,260 shares, with a net purchase of 7,260 shares. During the past 18 months, 16,956 shares of Talphera Inc (TLPH) were sold and 37,260 shares were bought by its insiders, resulting in a net purchase of 20,304 shares.

Talphera Inc (TLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Talphera Inc Insider Transactions

No Available Data

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Skyline Venture Management Iv, Llc is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

Skyline Venture Management Iv, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Skyline Venture Management Iv, Llc. You might contact Skyline Venture Management Iv, Llc via mailing address: 525 University Ave., Suite 520, Palo Alto Ca 94301.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.